Home / Lab values A to Z / Alanine Aminotransferase (ALT)

High ALT (Alanine Aminotransferase) in Dogs: Clinical Meaning and Next Steps

Serum alanine aminotransferase elevation in dogs indicates hepatocellular leakage from acute or chronic liver disease, but can also result from severe skeletal muscle necrosis, systemic infection, or subclinical cellular changes induced by drugs such as phenobarbital or rifampicin.^1,2,3,4

By Vetinuity, founded by Brian Toncray, DVM, emergency veterinarian · October 26, 2026

Alanine aminotransferase is a cytosolic enzyme present predominantly within hepatocytes, though molecular evaluation reveals gene expression across cardiac muscle, skeletal muscle, adipose tissue, brain, and kidney tissue. Because of its concentration within hepatic cytoplasm, leakage of alanine aminotransferase into circulation serves as a primary surrogate marker for hepatocellular injury. Elevated serum activity occurs following cell membrane alteration or necrosis caused by acute hepatotoxicity, bacterial hepatic abscessation, infectious canine ehrlichiosis, or chronic inflammatory hepatitis. However, non-hepatic pathology such as severe skeletal muscle necrosis can also release significant enzyme activity into blood without concurrent hepatic damage. Furthermore, therapeutic administration of medications including phenobarbital, rifampicin, or thalidomide can elevate serum activity through subclinical cellular injury or altered membrane permeability, requiring careful diagnostic differentiation.^1,2,3,5

How far the result sits from the interval

Hepatocellular Damage and Hepatic Infectious Causes

Increased serum alanine aminotransferase activity serves as a classic surrogate marker for tissue injury and hepatocellular damage due to the abundance of enzyme protein within liver cells. In dogs presenting with hepatic abscessation, elevated activity of alanine aminotransferase is documented in 40 of 50 evaluated patients, frequently accompanied by neutrophilia, toxic neutrophil changes, fever, hyporexia, and abdominal pain. Hepatic abscesses, which can range from small lesions to large solitary or multifocal masses, are commonly associated with bacterial isolates such as Escherichia coli and may occur secondary to underlying hepatic neoplasia. Severe systemic infectious diseases such as Ehrlichia canis can also trigger hepatomegaly and elevated serum alanine aminotransferase alongside anemia, thrombocytopenia, hyperglobulinemia, and azotemia.^1,4,9

Immune-mediated and chronic inflammatory liver diseases represent major causes of sustained alanine aminotransferase elevation in canine practice. In Doberman Pinschers with chronic hepatitis, autoantibody activity against histones is detected in 92 percent of subclinical cases and 84.6 percent of clinically affected dogs, establishing circulating antihistone autoantibodies as a valuable screening tool when elevated serum enzyme activity is identified prior to clinical decompensation. Longitudinal evaluation of clinically healthy dogs with incidental alanine aminotransferase elevations demonstrates that only a small proportion develop clinically relevant liver failure, but early identification allows timely intervention.^10,11

Medication Effects, Toxins, and Non-Hepatic Sources

Elevated serum alanine aminotransferase activity does not originate exclusively from primary liver lesions or non-pharmacologic injury. Administration of therapeutic agents such as rifampicin results in alanine aminotransferase elevations in 26.59 percent of treated dogs, with risk increasing significantly when treatment duration exceeds 19 days or when co-administered with nonsteroidal anti-inflammatory drugs, cephalosporins, or trimethoprim-sulfamethoxazole. Similarly, administration of phenobarbital to epileptic dogs frequently elevates serum enzyme activity; liver biopsy homogenates demonstrate that this elevation stems from subclinical hepatocellular injury and structural alterations rather than hepatic enzyme induction. Anti-neoplastic therapy with thalidomide can also cause increased enzyme activity in a subset of tumor-bearing dogs.^2,5,8

Non-hepatic tissue injury must be considered when evaluating elevated serum alanine aminotransferase. Tissue distribution analysis shows robust canine alanine aminotransferase-1 gene expression in cardiac tissue, gastrocnemius muscle, fat, and brain tissue. Severe ongoing skeletal muscle degeneration, such as that seen in canine X-linked muscular dystrophy, causes persistent increases in serum alanine aminotransferase activity alongside creatine kinase and aspartate aminotransferase without evidence of hepatic degeneration or sorbitol dehydrogenase elevation. Accidental ingestion of toxic substances like chocolate also produces mild enzyme elevations alongside sinus tachycardia, hyperthermia, and agitation.^3,6,12

Diagnostic Evaluation and Monitoring Protocol

When evaluating a dog with elevated serum alanine aminotransferase activity, initial assessment requires distinguishing true hepatocellular injury from extrahepatic muscle necrosis, drug toxicity, or assay cofactor deficiency. Measuring concurrent serum creatine kinase and sorbitol dehydrogenase activity clarifies whether skeletal muscle damage is responsible for circulating enzyme activity. Routine laboratory methods measuring alanine aminotransferase may yield falsely low results if the apoenzyme lacks pyridoxal-5-phosphate, making laboratory assay methodology an important consideration when enzyme results conflict with clinical presentation. In cats, measuring serum microRNA-122 concentrations shows a strong positive correlation with serum alanine aminotransferase activity and serves as a specific biomarker for hepatocellular injury.^7,3,13

Follow-up testing for dogs with confirmed hepatic enzyme elevations should include baseline liver function testing, including preprandial and postprandial serum bile acids, blood urea nitrogen, albumin, and total bilirubin. Abdominal ultrasonography is indicated to assess hepatic parenchymal architecture, screen for focal or multifocal hepatic abscesses, and identify concurrent biliary or neoplastic disease. For patients receiving potentially hepatotoxic medications such as rifampicin, baseline biochemistry screening prior to initiating treatment followed by weekly serum monitoring is recommended to detect early subclinical hepatotoxicity.^1,4,8

Example: a result worked through

Vetinuity assists practicing veterinarians by instantly reading flagged alanine aminotransferase results from uploaded chemistry printouts and automatically updating the diagnostic differential list to include hepatic, muscle, and drug-induced etiologies. See how Vetinuity reads a lab printout.